Showing 1391-1400 of 1861 results for "".
- SkinCeuticals, Aesthetics Biomedical Join Forces for Vivace Experience Featuring SkinCeuticals C E Ferulichttps://practicaldermatology.com/news/skinceuticals-aesthetics-biomedical-join-forces-for-vivace-experience-featuring-skinceuticals-c-e-ferulic/2460558/SkinCeuticals is teaming up Aesthetics Biomedical’s Vivace Fractional Micro Needle Radio Frequency Treatment to create the professional Vivace Experience featuring SkinCeuticals C E Ferulic MaryAnn Guerra, CEO & President of Aesthetics Biomedical states, "Aesth
- It's a Deal: Allergan Buys Luminera Dermal-Filler Businesshttps://practicaldermatology.com/news/its-a-deal-allergan-buys-luminera-dermal-filler-business/2460556/Allergan Aesthetics, an AbbVie company, has acquired Luminera's full dermal filler portfolio and R&D pipeline. Luminera is a privately held aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. "
- Practical Dermatology® magazine, Modern Aesthetics® magazine Recognized For Excellence by Folio: Magazinehttps://practicaldermatology.com/news/practical-dermatology-magazine-modern-aesthetics-magazine-recognized-for-excellence-by-folio-magazine/2460546/Bryn Mawr Communications III, LLC is pleased to announce that Practical Dermatology® magazine and sister publication Modern Aesthetics® magazine took home two Honorable Mentions from Folio: Magazine’s 2020 Eddie & Ozzie Awards, including a nod for Editorial Tea
- Dr. Rafael Sierra is Cynosure's Newest R&D Advisorhttps://practicaldermatology.com/news/dr-rafael-sierra-is-cynosures-newest-rd-advisor/2460533/Rafael Sierra, PhD is back at Cynosure. The former Chief Technology Officer is now an R&D Advisor. "Dr. Sierra's passion for the science behind medical aesthetics and inherent knowledge of its clinical application are unparalleled," says Todd
- ICYMI: ASA Honors Drs. Doris Day and Mark Lebwohl at Virtual Galahttps://practicaldermatology.com/news/icymi-asa-honors-drs-doris-day-and-mark-lebwohl-at-virtual-gala/2460521/Dermatologists Drs. Doris Day and Mark Lebwohl took home top awards at the American Skin Association’s (ASA) annual gala, which was held virtually this year. Dr. Day, a clinical associate professor of dermatology at NYU Langone Medical Center, received ASA's Excellen
- Cassiopea Scores FDA Approval for Winlevi (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptorhttps://practicaldermatology.com/news/cassiopea-scores-fda-approval-for-winlevi-clascoterone-cream-1-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor/2460513/The FDA has approved Winlevi (clascoterone cream 1%) for the treatment of acne in patients 12 years and older. "Th
- Verrica Pharmaceuticals Names New Clinical and Drug Development Leadership Team Membershttps://practicaldermatology.com/news/verrica-pharmaceuticals-names-new-clinical-and-drug-development-leadership-team-members/2460509/Verrica Pharmaceuticals Inc. announced key appointments to its drug development team. Current Board of Directors member Gary Goldenberg, MD, a thought leader in the field of dermatology, stepped down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Dr. Law
- Lumenis Introduces NuEra Tighthttps://practicaldermatology.com/news/lumenis-introduces-nuera-tight/2460502/Lumenis is rolling out the NuEra Tight with FocalRF technology for body contouring. NuEra Tight will be available worldwide starting with the United States in August 2020 and Europe, the Middle East and Asia later this year. "Radio Frequency treatments are among the most
- Study: Pembrolizumab Provides Long-Term Benefits in Patients With Metastatic Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-provides-long-term-benefits-in-patients-with-metastatic-melanoma/2460470/A new 10-year analysis provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (Keytruda). This retrospective analysis of three ra
- Leo Pharma: FDA Accepts BLA for Tralokinumab for ADhttps://practicaldermatology.com/news/leo-pharma-fda-accepts-bla-for-tralokinumab-for-ad/2460462/The FDA has accepted the Biologics License Application (BLA) for Leo Pharma’s tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD), the company says. A taget action date has been set in the second quarter of 2021. Tralokinumab is a fully human mo